Predictors of very early stroke recurrence in the POINT trial population.

ABSTRACT:

Background

Recent trials of acute secondary prevention in patients with minor ischemic stroke or transient ischemic attack (TIA) have demonstrated high rates of early recurrence within days of the initial event. Identifying clinical features associated with early recurrence may guide focused management.

Methods

Using logistic regression applied to the data of the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, we evaluated what baseline clinical factors predict outcome events occurring within 7 days of randomization.

Results

In the POINT trial, 181 subjects (3.7%) had early recurrence, defined as primary outcome events within 7 days of trial entry, whereas only 100 outcome events occurred over the remainder of the 90 day trial. Protect

SUBMITTER: Bourand N 

PROVIDER: S-EPMC9107185 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature